Association between antidepressant half-life and the risk of suicidal ideation or behavior among children and adolescents: confirmatory analysis and research implications
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Authors
Smith, Eric G.UMass Chan Affiliations
Department of PsychiatryDocument Type
Journal ArticlePublication Date
2009-04-01Keywords
AdolescentAntidepressive Agents
effects
Child
Clinical Trials as Topic
Depressive Disorder
Dose-Response Relationship, Drug
Half-Life
Humans
Risk Assessment
Risk Factors
Serotonin Uptake Inhibitors
effects
*Suicide
*Suicide, Attempted
United States
United States Food and Drug Administration
Psychiatry
Metadata
Show full item recordAbstract
BACKGROUND: This study sought to determine from a recent meta-analysis of pediatric antidepressant trials if a general property of antidepressant medications--the multiple-dosing medication half-life--is associated with risks for suicidal ideation or behavior. METHODS: Relative risks for suicidal behavior (ideation, attempt, or preparation) for seven antidepressants were obtained from both the FDA's initial and published versions of their pediatric antidepressant meta-analysis. The correlation between the relative risk for suicidal behavior and antidepressant half-life was examined using a nonparametric test, Spearman's rho. RESULTS: A significant correlation (rho=0.929; p=0.003) was observed for the initial analysis, as previously reported by Weiss and Gorman. The correlation was robust to a change in the suicidality ranking for the longest half-life medication, fluoxetine, that occurred when results from the Treatment of Adolescent Depression Study (TADS) were included in the published meta-analysis (rho=0.786, p=0.036). LIMITATIONS: In addition to limitations common to meta-analyses, our analysis has additional uncertainties including the fact that adult, rather than pediatric, antidepressant half-life data were used due to an unavailability of published information. In addition, risks for suicidal ideation/behavior may vary for reasons other than half-life (e.g. study eligibility criteria, illness severity or responsiveness to treatment, diagnoses, etc.). CONCLUSIONS: The risk of suicidal ideation or behavior in short-term antidepressant trials involving children or adolescents, as defined in the recent FDA meta-analysis, appears to be potentially at least partly associated with antidepressant half-life. Although any relationship is tentative, approaches to investigating several potential candidate mechanisms for any association are discussed.Source
J Affect Disord. 2009 Apr;114(1-3):143-8. Epub 2008 Aug 8. Link to article on publisher's siteDOI
10.1016/j.jad.2008.06.018Permanent Link to this Item
http://hdl.handle.net/20.500.14038/45992PubMed ID
18692250Related Resources
Link to Article in PubMedae974a485f413a2113503eed53cd6c53
10.1016/j.jad.2008.06.018